Advertisement

AAPS PharmSciTech

, Volume 18, Issue 8, pp 3247–3257 | Cite as

Development of Aerosol Phospholipid Microparticles for the Treatment of Pulmonary Hypertension

  • Sarah Brousseau
  • Zimeng Wang
  • Sweta K. Gupta
  • Samantha A. Meenach
Research Article

Abstract

Pulmonary arterial hypertension (PAH) is an incurable cardiovascular disease characterized by high blood pressure in the arteries leading from the heart to the lungs. Over two million people in the USA are diagnosed with PAH annually and the typical survival rate is only 3 years after diagnosis. Current treatments are insufficient because of limited bioavailability, toxicity, and costs associated with approved therapeutics. Aerosol delivery of drugs is an attractive approach to treat respiratory diseases because it increases localized drug concentration while reducing systemic side effects. In this study, we developed phospholipid-based aerosol microparticles via spray drying consisting of the drug tacrolimus and the excipients dipalmitoylphosphatidylcholine and dipalmitoylphosphatidylglycerol. The phospholipid-based spray-dried aerosol microparticles were shown to be smooth and spherical in size, ranging from 1 to 3 μm in diameter. The microparticles exhibited thermal stability and were amorphous after spray drying. Water content in the microparticles was under 10%, which will allow successful aerosol dispersion and long-term storage stability. In vitro aerosol dispersion showed that the microparticles could successfully deposit in the deep lung, as they exhibited favorable aerodynamic diameters and high fine particle fractions. In vitro dose-response analysis showed that TAC is nontoxic in the low concentrations that would be delivered to the lungs. Overall, this work shows that tacrolimus-loaded phospholipid-based microparticles can be successfully created with optimal physicochemical and toxicological characteristics.

KEY WORDS

pulmonary arterial hypertension microparticles aerosol delivery spray drying phospholipid 

Notes

ACKNOWLEDGEMENTS

The authors gratefully acknowledge financial support from an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM103430. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Finally, the authors thank RI-INBRE for UPLC access and RIN2 for SEM, PXRD, and DSC access.

COMPLIANCE WITH ETHICAL STANDARDS

Conflict of Interest

No conflicts of interest exist.

REFERENCES

  1. 1.
    Archer S, Weir E, Wilkins M. Basic science of pulmonary arterial hypertension for clinicians new concepts and experimental theories. Circulation. 2010;121(18):2045–U175.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Saigal A, Ng WK, Tan RBH, Chan SY. Development of controlled release inhalable polymeric microspheres for treatment of pulmonary hypertension. Int J Pharm. 2013;450:114–22.CrossRefPubMedGoogle Scholar
  3. 3.
    Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J am Coll Cardiol. 2004;43(12s1):S13–24.CrossRefGoogle Scholar
  4. 4.
    Spiekerkoetter E, Tian X, Cai J, Hopper R, Sudheendra D, Li C, et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Investig. 2013;123(8):3600–13.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv rev. 2006;58:1009–29.CrossRefPubMedGoogle Scholar
  6. 6.
    Li X, Mansour HM. Physicochemical characterization and water vapor sorption of organic solution advances spray-dried inhalable trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery. AAPS PharmSciTech. 2011;12(4).Google Scholar
  7. 7.
    Meenach SA, Vogt FG, Anderson KW, Hilt JZ, McGarry RC, Mansour HM. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. Int J Nanomedicine. 2013;8:275–93.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Bosquillon C, Lombry C, Preat V, Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release. 2001;70(3):329–39.CrossRefPubMedGoogle Scholar
  9. 9.
    Iskandar F, Gradon L, Okuyama K. Control of the morphology of nanostructured particles prepared by the spray drying of a nanopartcile sol. J Colloid Interface Sci. 2003;265(3):296–303.CrossRefPubMedGoogle Scholar
  10. 10.
    Hoe S, Ivey JW, Boraey MA, Shamsaddini-Shahrbabak A, Javaheri E, Matinkhoo S, et al. Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery. Pharm res. 2014;31:449–65.CrossRefPubMedGoogle Scholar
  11. 11.
    Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary delivery. Pharmaceutical Research. 2007;24(3).Google Scholar
  12. 12.
    Meenach SA. High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physiochemical characterization, in vitro aerosol dispersion, and cellular studies. AAPS PharmSciTech. 2014;15(6):1574–87.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ré M-I. Formulating drug delivery systems by spray drying. Dry Technol. 2006;24:433–46.CrossRefGoogle Scholar
  14. 14.
    Hong K-H, Lee YJ, Lee E, Park SO, Han C, Beppu H, et al. Genetic ablation of the Bmpr2 gene in pulmonary endothelium is sufficient to predispose to pulmonary hypertension. Circulation. 2008;118(7):722–30.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156–63.CrossRefPubMedGoogle Scholar
  16. 16.
    Cho JH. Development of novel fast-dissolving tacrolimus solid-dispersion-loaded prolonged release tablet. Eur J Pharm Sci. 2014:1–7.Google Scholar
  17. 17.
    Gao S, Sun J, Fu D, Zhao H, Lan M, Gao F. Preparation, characterization and pharmacokinetic studies of tacrolimus-dimethyl-ß-cyclodextrin inclusion complex-loaded albumin. Int J Pharm. 2012;427:410–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Watts AB, Peters JI, Talbert RL, O'Donnell KP, Coalson JJ, Williams RO. Preclinical evaluation of tacrolimus colloidal dispersion for inhalation. Eur J Pharm Biopharm. 2011;77(2):207–15.CrossRefPubMedGoogle Scholar
  19. 19.
    Gupta V, Gupta N, Shaik IH, Mehvar R, McMurtry IF, Oka M, et al. Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. J Control Release. 2013;167(2):189–99.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hayes DJ, Zwischenberger JB, Mansour HM. Aerosolized tacrolimus: a case report in a lung transplant recipient. Transplant Proc. 2010;42:3876–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Schrepfer S, Deuse T, Reichenspurner H, Hoffmann J, Haddad M, Fink J, et al. Effect of inhaled tacrolimus on cellular and humoral rejection to prevent posttransplant obliterative airway disease. Am J Transplant. 2007;7(7):1733–42.CrossRefPubMedGoogle Scholar
  22. 22.
    Wang Z, Cuddigan JL, Gupta SK, Meenach SA. Nanocomposite microparticles (nCmP) for the delivery of tacrolimus in the treatment of pulmonary arterial hypertension. Int J Pharm. 2016;512(1):305–13.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Chen L, Nakano K, Kimura S, Matoba T, Iwata E, Miyagawa M, et al. Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression to monocrotaline-induced pulmonary artery hypertension. Hypertension. 2011;57(2):343–50.CrossRefPubMedGoogle Scholar
  24. 24.
    Kimura S, Egashira K, Chen L, Nakano K, Iwata E, Miyagawa M, et al. Nanoparticle-mediated delivery of nuclear factor κB into lung ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension. 2009;53(5):577–83.CrossRefGoogle Scholar
  25. 25.
    Evora C, Soriano I, Rogers RA, Shakesheff KM, Hanes J, Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J Control Release. 1998;51(2–3):143–52.CrossRefPubMedGoogle Scholar
  26. 26.
    Mansour H, Wang DS, Chen CS, Zografi G. Comparison of bilayer and monolayer properties of phospholipid systems containing dipalmitoylphosphatidylglycerol and dipalmitoylphosphatidylinositol. Langmuir. 2001;17(21):6622–32.CrossRefGoogle Scholar
  27. 27.
    Alves GP, Santana MHA. Phospholipid dry powders produced by spray drying processing: structural, thermodynamic and physical properties. Powder Technol. 2004;145:139–48.CrossRefGoogle Scholar
  28. 28.
    Mansour HM, Sohn M, Al-Ghananeem A, DeLuca PP. Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects. Int J Mol Sci. 2010;11(9):3298–322.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Mansour HM, Xu Z, Meenach SA, Deluca PP. Novel drug delivery systems: inhalation aerosols, pulmonary/nasal drug delivery, and nanomedicine. In: Mitra A, editor. Drug Delivery 2013.Google Scholar
  30. 30.
    Meenach SA, Anderson KW, Hilt JZ, McGarry RC, Mansour HM. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur J Pharm Sci. 2013;49(4):699–711.CrossRefPubMedGoogle Scholar
  31. 31.
    Abramoff MD, Magalhaes PJ, Ram SJ. Image processing with ImageJ. Biophoton Int. 2004;11(7):36–42.Google Scholar
  32. 32.
    Hickey AJ, Mansour HM. Delivery of drugs by the pulmonary route. In: Florence AT, Siepmann J, editors. Modern pharmaceutics. 2. 5th ed. New York: Taylor and Francis; 2009. p. 191–219.Google Scholar
  33. 33.
    Finlay WH. The mechanics of inhaled pharmaceutical aerosols: an introduction. London: Academic Press; 2001.Google Scholar
  34. 34.
    Mansour HM, Zografi G. The relationship between water vapor absorption and desorption by phospholipids and bilayer phase transitions. J Pharm Sci. 2007;96(2):377–96.CrossRefPubMedGoogle Scholar
  35. 35.
    Mansour HM, Zografi G. Relationships between equilibrium spreading pressure and phase equilibria of phospholipid bilayers and monolayers at the air-water interface. Langmuir. 2007;23:3809–19.CrossRefPubMedGoogle Scholar
  36. 36.
    Wu X, Hayes DJ, Zwischenberger JB, Kuhn RJ, Mansour HM. Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation. Drug des Devel Ther. 2013;7:59–72.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25(12):563–70.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2017

Authors and Affiliations

  • Sarah Brousseau
    • 1
  • Zimeng Wang
    • 1
  • Sweta K. Gupta
    • 1
  • Samantha A. Meenach
    • 1
    • 2
  1. 1.Department of Chemical EngineeringUniversity of Rhode IslandKingstonUSA
  2. 2.Department of Biomedical and Pharmaceutical SciencesUniversity of Rhode IslandKingstonUSA

Personalised recommendations